Methotrexate‐Loaded Liposomal Formulation Enables 6‐Week Sustained Intraocular Therapeutic Drug Release in a Porcine Model (Adv. Healthcare Mater. 1/2026)

Advanced Healthcare Materials 2026 Open access

Read full text
Authors: Maximilian Hammer, Lea Skrzypczyk, Sabrina Wohlfart, Bryan Calder Ackermann, Ludwig Geisweid, Simon William Pohl, Margarita Karaivanova, Jonathan Herth, Victor Aristide Augustin, Alexander Studier‐Fischer, Tina Sackmann, Leon D. Kaulen
+6 more Anna M. Steyer, Walter Mier, David H Steel, Kanmin Xue, Gerd Uwe Auffarth, Philipp Uhl
DOI: 10.1002/adhm.70540
Cited by: 0

Abstract

Intraocular Drug Delivery In the Research Article (DOI: 10.1002/adhm.202503230), Philipp Uhl and co-workers develop a liposomal methotrexate formulation, which enables minimally invasive, sustained intraocular drug delivery for over six weeks with single injection. Developed for treating intraocular diseases like lymphoma and proliferative vitreoretinopathy, it offers excellent biocompatibility in a porcine model. This innovative approach is non-inferior to repetitive bi-weekly injections of free methotrexate, providing a safer, and cost-effective alternative.

Fields of Study & Subjects

Advanced Drug Delivery Systems Ocular Disorders and Treatments Ocular Diseases and Behçet’s Syndrome

Publication details

Journal / source
Advanced Healthcare Materials
Volume
15
Issue
1
Publication date
1 January 2026
Language
EN